Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

5.95
+0.10001.71%
Post-market: 5.10-0.8500-14.29%19:59 EST
Volume:1.22M
Turnover:6.97M
Market Cap:326.64M
PE:-10.62
High:6.00
Open:5.77
Low:5.72
Close:5.85
52wk High:13.68
52wk Low:4.25
Shares:54.90M
Float Shares:45.48M
Volume Ratio:1.94
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5600
EPS(LYR):-1.7420
ROE:-70.17%
ROA:-43.25%
PB:4.08
PE(LYR):-3.42

Loading ...

Candel Therapeutics Announces Pricing Of Public Offering Of 18,348,624 Shares At $5.45 Each

Reuters
·
3 hours ago

Candel Therapeutics Inc - Prices Public Offering of 18,348,624 Shares at $5.45 Each

THOMSON REUTERS
·
3 hours ago

Candel Therapeutics Secures $100M Royalty Funding for CAN-2409

TIPRANKS
·
8 hours ago

BRIEF-Candel Therapeutics Announces Proposed $100 Million Public Offering

Reuters
·
8 hours ago

BUZZ-Candel Therapeutics falls after announcing $100 mln stock offering, royalty agreement

Reuters
·
8 hours ago

Candel Therapeutics announces $100M common stock offering

TIPRANKS
·
8 hours ago

Candel Therapeutics Inc - Proceeds to Fund Aglatimagene Launch and Phase 3 Trial Costs

THOMSON REUTERS
·
9 hours ago

Candel Therapeutics Secures $100M Royalty Funding Agreement With RTW Investments

Reuters
·
9 hours ago

Candel Therapeutics: Under Agreement, Rtw Will Receive a Tiered Single Digit Percentage of Annual Net Sales of Aglatimagene in U.S. Subject to a Cap

THOMSON REUTERS
·
9 hours ago

Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit

Reuters
·
Feb 11

Candel Therapeutics Showcases Clinical Trial Data for CAN-3110 in Recurrent High-Grade Glioma

Reuters
·
Feb 11

Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update

TIPRANKS
·
Feb 06

BRIEF-Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Feb 03

Candel Therapeutics Grants New Employee Stock Options Under 2025 Inducement Plan

Reuters
·
Feb 03

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 03

Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)

Simply Wall St.
·
Jan 17

Candel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy

Reuters
·
Jan 12

Candel Therapeutics Showcases Advances in Immune-Based Cancer Therapies in New Corporate Presentation

Reuters
·
Dec 11, 2025

Candel Therapeutics Price Target Maintained With a $15.00/Share by Stephens & Co.

Dow Jones
·
Dec 08, 2025

Candel Therapeutics Q3 Net Income USD -11.269 Million

Reuters
·
Nov 20, 2025